Cardioprotective effects of compound ALM-802 on subendocardial ischemia models
Open Access
- 27 September 2021
- journal article
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 1,p. 18-22
- https://doi.org/10.37489/2587-7836-2021-1-18-22
Abstract
The investigation purpose. N1-(2,3,4-trimethoxybenzyl)-N2-{2-[(2,3,4-trimethoxybenzyl)amino]ethyl}-1,2-ethanediamine (ALM-802 compounds) cardioprotective effect has been studied in rat models of subendocardial ischemia caused by isoproterenol and dobutamine. Material and methods. Acute subendocardial myocardial ischemia in anesthetized rats (urethane 1300 mg/kg, i.p.) was caused by infusion of isoproterenol (20 µg/kg/min i.v.) or dobutamine (80 µg/kg/min i.v.). Results. It was shown that in anesthetized rats, isoproterenol and dobutamine caused almost the same ST-segment depression in the II standard ECG lead. The compound ALM-802 (2 mg/kg i.v.), administered 2 minutes before the infusion start of isoproterenol or dobutamine, equally prevented the occurrence of ischemic changes on the ECG. Conclusion. The non-selective beta-adrenomimetic isoproterenol and the selective β1-adrenomimetic dobutamine cause subendocardial ischemia of the same intensity in anesthetized rats. The compound ALM-802 has a pronounced anti-ischemic effect on both models.Keywords
This publication has 8 references indexed in Scilit:
- Anti-Ischemic Activity of Triamine ALM-802 under Conditions of Endothelial DysfunctionBulletin of Experimental Biology and Medicine, 2019
- Myocardial Energy Substrate Metabolism in Heart Failure : from Pathways to Therapeutic TargetsCurrent Pharmaceutical Design, 2015
- Targeting fatty acid and carbohydrate oxidation — A novel therapeutic intervention in the ischemic and failing heartBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2011
- Metabolic remodelling in human heart failureCardiovascular Research, 2011
- Anti-anginal effects of partial fatty acid oxidation inhibitorsCurrent Opinion in Pharmacology, 2007
- Metabolic remodelling of the failing heart: the cardiac burn-out syndrome?Cardiovascular Research, 2004
- The Use of Partial Fatty Acid Oxidation Inhibitors for Metabolic Therapy of Angina Pectoris and Heart FailureHerz, 2002
- Effect of an Orally Active Na + /H + Exchange Inhibitor, SMP-300, on Experimental Angina and Myocardial Infarction Models in RatsJournal of Cardiovascular Pharmacology, 2002